Advertising Law Blog

Andrew Lustigman, head of Olshan’s Advertising, Marketing & Promotions Practice Group, was quoted in a Law360 article about the Federal Trade Commission’s suit against A&O Enterprises Inc. for making false claims about their intravenous therapy products.  The claims were allegedly not backed by scientific research such as the ability of their products to treat diseases  including cancer and multiple sclerosis.  This was the first time the FTC has taken a disciplinary action against a company that distributes IV Cocktails.  The health risk that these claims possess influenced the FTC’s swiftness in their settlement against the company’s marketing.  Mr. Lustigman was quoted as saying, “Along with health and safety claims, the FTC is particularly focused on claims about treating diseases.”